Intellia Therapeutics (NASDAQ:NTLA) CEO Sells $107,910.00 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John Leonard sold 9,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the transaction, the chief executive officer owned 1,138,064 shares in the company, valued at $13,645,387.36. This trade represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Intellia Therapeutics Stock Up 1.7%

NASDAQ:NTLA traded up $0.20 on Tuesday, reaching $11.86. 2,874,316 shares of the company’s stock were exchanged, compared to its average volume of 5,128,988. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -3.53 and a beta of 1.80. The business has a fifty day moving average of $12.21 and a 200-day moving average of $13.06. Intellia Therapeutics, Inc. has a 52-week low of $7.95 and a 52-week high of $18.48.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business had revenue of $7.66 million during the quarter, compared to analyst estimates of $12.98 million. During the same quarter last year, the firm posted ($0.98) earnings per share. The business’s revenue for the quarter was down 46.4% compared to the same quarter last year. As a group, equities analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Barclays began coverage on Intellia Therapeutics in a report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price target on the stock. Citizens Jmp restated a “market outperform” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Wall Street Zen lowered shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Evercore upgraded shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective for the company in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and an average target price of $20.57.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC lifted its position in shares of Intellia Therapeutics by 289.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company’s stock valued at $26,000 after acquiring an additional 1,594 shares during the period. Parallel Advisors LLC increased its stake in Intellia Therapeutics by 267.0% in the 3rd quarter. Parallel Advisors LLC now owns 2,268 shares of the company’s stock valued at $27,000 after purchasing an additional 1,650 shares in the last quarter. Freestone Grove Partners LP acquired a new position in Intellia Therapeutics during the second quarter worth $33,000. Nykredit A S acquired a new position in Intellia Therapeutics during the second quarter worth $33,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Intellia Therapeutics during the second quarter worth $34,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.